Please login to the form below

Not currently logged in
Email:
Password:

Stem Cell Therapeutics

This page shows the latest Stem Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bayer takes control of BlueRock stem cell joint venture

Bayer takes control of BlueRock stem cell joint venture

Deal values BlueRock at $1bn. Bayer is buying out private equity partner Versant Ventures and founders in its cell therapy joint venture BlueRock Therapeutics for $240m, three years after setting up ... The start-up intends to develop off-the-shelf

Latest news

  • Bayer helps bankroll new stem cell company BlueRock Bayer helps bankroll new stem cell company BlueRock

    Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies. There is a new player on the stem cell therapy stage, thanks to $225m in start-up funding from Bayer ... BlueRock's founding and scientific investigation team

  • Orphan status for Stem Cell's leukaemia drug Orphan status for Stem Cell's leukaemia drug

    Tigecycline wins FDA rare disease designation. US regulators have granted orphan drug status to tigecycline, a cancer drug in development by Stem Cell Therapeutics. ... Tigecycline is being investigated by Stem Cell Therapeutics for its use in the

  • UK regenerative medicine projects get £8.5m boost

    Novel stem cell manufacturing technologies. • Cell labelling and tracking technologies for quality control and monitoring in the body. • ... Regenerative medicine is an interdisciplinary approach that spans tissue engineering, developmental and stem

  • Survival strategy

    Licenser/Partner. Product/Technology. Development status. Headline ($m). Mesoblast/Cephalon. Stem cell therapeutics in CHF. ... Immunotherapy company acquisition.  . 428. Theramex/Teva. Branded product company acquisition.  . 368. Evotec/MedImmune.

  • Diabetes favoured

    and Oncomed's $428m strategic alliance with Bayer Schering Pharma (BSP) to discover, develop and commercialise novel anti-cancer stem cell therapeutics. ... Anti-cancer stem cell therapy platform. Discovery. 428. Ascenta Therapeutics/sanofi-aventis.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation.  Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast   . ... Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. †Hutchison MediPharma / Eli Lilly.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...